07 December 2020
The technology provider for 3D printed prescription lenses, Luxexcel, has celebrated reaching over 50,000 lenses printed for customers through its manufacturing platforms in the US and Europe.
The company’s VisionPlatform solution has printed over 50,000 lenses for customers in the traditional and smart eyewear and high-tech industries.
Forming part of Luxexcel’s volume manufacturing technology, the platform enables customers and partners to commercially 3D print traditional or smart lenses with individualised prescription requirements.
Fabio Esposito, chief executive officer at Luxexcel, commented: “The exponential growth we’re achieving in the production in volume of 3D printed lenses on our platforms is a milestone to enable customers to combine prescription eyewear with smart technology.”
Luxexcel scaled the platform for volume manufacturing, also aiming to make it more predictable and flexible.
Chief strategy officer at Luxexcel, Guido Groet, added: “Together with our customers, we’ve now proven that VisionPlatform is stable and offers scalability, with the flexibility to create large volumes of lenses with individualized specifications, and prescription power.”
Mr Groet observed that customers and partners have used the platform to produce unique lenses “which aren’t possible to manufacture with legacy eyewear technologies.”
“Customers use VisionPlatform to make better products with enhanced functionality that also address the vision correction needs of glasses wearers,” he continued.
Speaking to OT last year, when the platform had printed over 5000 lenses, Mr Esposito shared the company’s work to industrialise the VisionPlatform. The company described its aims to enable the addition of prescriptions to smart eyewear: “3D printing is uniquely positioned to bridge the gap between traditional lenses and the future of eyewear which resides in smart functionalities.”
The company aims to work with lens manufacturers, providing its 3D printing technology.
Comments (0)
You must be logged in to join the discussion. Log in